WIDER COPAY DIFFERENTIALS PROMOTE GENERIC DISPENSING

SEPTEMBER 01, 2007

A new study by researchers at Express Scripts has confirmed a connection between the copay differentials for brand and generic drugs set by drug plans and the willingness of patients to use lower-cost generic medicines. According to the study, plans with a generic versus brand copayment differential of $21 or more used generic drugs at a rate 5.2% higher than those with a differential of $5 or less.

?The findings in this study show that getting plan design right pays off, given that a 1% increase in generic use results in an estimated 1.6% decrease in total drug-plan costs,? a spokesman for the researchers said. The study, published in the June 2007 issue of the American Journal of Managed Care, also found that plans with $16 to $20 differentials used generic drugs at rates that were 2.9% higher than those with the lowest differential between generic and brand copayments.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.